E7389-LF

liposomal irinotecan · Eisai Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for E7389-LF, covering 2026-02-10 to 2026-02-10. Get the full timeline:

Most recent: Clinical Trial Update: A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor [Phase 1, Phase 2]

See pricing